H. Demirhindi, E. Nazlican and M. Akbada, “Cervical Cancer Screening in Turkey: A Community-Based Experience after 60 Years of Pap Smear Usage,” Asian Pacific Journal Cancer Prevention, Vol. 13, No. 12, 2012, pp. 6497-6500. http://dx.doi.org/10.7314/APJCP.2012.13.12.6497
 M. Maalej, K. Mrad, L. Kochbati, et al., “Cervical Cancer in Tunisia: An Epidemiological, Clinical and Pathological Study,” European Journal of Obstetrics & Gynecology and Reproductive Biology, Vol. 113, No. 2, 2004, pp. 226-228. http://dx.doi.org/10.1016/j.ejogrb.2003.07.005
 H. H. Nguyen. T. R. Broker and L. T. Chow, “Immune Responses to Human Papillomavirus in Genital Tract of Women with Cervical Cancer,” Gynecologic Oncology, Vol. 96, No. 2, 2005, pp. 452-461. http://dx.doi.org/10.1016/j.ygyno.2004.10.019
 E. L. Franco, “Cancer Causes Revisited: Human Papillomavirus and Cervical Neoplasia,” Journal of the National Cancer Institute, Vol. 87, No. 11, 1995, 779-780. http://dx.doi.org/10.1093/jnci/87.11.779
 N. Munoz, F. X. Bosch, S. de Sanjosé, et al., “International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer,” The New England Journal of Medicine, Vol. 348, 2003, pp. 518-527. http://dx.doi.org/10.1056/NEJMoa021641
 J. S. Smith, L. Lindsay, B. Hoots, et al., “Human Papillomavirus Type Distribution in Invasive Cervical Cancer and High-Grade Cervical Lesions: A Meta-Analysis Update,” International Journal of Cancer, Vol. 121, No. 3, 2007, pp. 621-632. http://dx.doi.org/10.1002/ijc.22527
 P. Sehr, K. Zumbach and M. Pawlita, “A Generic Capture ELISA for Recombinant Proteins Fused to Glutathione S-Transferase: Validation for HPV Serology,” Journal of Immunological Methods, Vol. 253, No. 1-2, 2001, pp. 153-162. http://dx.doi.org/10.1016/S0022-1759(01)00376-3
 W. Meschede, K. Zumbach, J. Braspenning, et al., “Antibodies against Early Proteins of Human Papillomavirus as Diagnostic Markers for Invasive Cervical Cancer,” Journal of Clinical Microbiology, Vol. 36, No. 2, 1998, pp. 475-480.
 L. Raymond, F. Menegoz, G. Fioretta, et al., “Recent Trends in Incidence of Cervical Cancer in Several Regions of Southern-Western Europe,” Revue d’Epidémiolologie et de Santé Publique, Vol. 43, 1995, pp. 122-126.
 K. D. Hatch, A. Schnader and M. W. Abdel Nour, “An Evaluation of Human Papillomavirus Testing for Intermediate and High Risk Types as Triage before Colposcopy,” American Journal of Obstetrics and Gynecology, Vol. 172, No. 4, 1995, pp. 1150-1157. http://dx.doi.org/10.1016/0002-9378(95)91473-0
 S. Cecchini, A. Iossa, S. Ciatto, et al., “Routine Colposcopic Survey of Patients with Squamous Atypia, a Method for Identifying Cases with False Negative Smears,” Acta Cytological, Vol. 34, No. 6, 1990, pp. 778-780.
 G. Body, Ph. Descamps, J. Lansac, et al., “Néoplasies Intra Epithéliales du col. Encyclopédie Médico-Chirurgicale en Gynécologie 597-A-10, Cancérologie 60-200-A-10. Paris,” Elsevier, 1993, p. 29.
 D. C. Slawson, J. H. Bennett and J. H. Herman, “Follow-Up to Papanicolaou Smear for Cervical Atypia Are We Missing Significant Disease? A Harnet Study,” Journal of Family Prost, Vol. 36, No. 3, 1993, pp. 289-293.
 N. C. Seckin, et al., “Routine Evaluation of Patients Persistent Inflammatory Cellular Changes on Pap Smear,” International Journal of Gynecology and Obstetrics, Vol. 59, No. 1, 1997, pp. 25-29. http://dx.doi.org/10.1016/S0020-7292(97)00113-6
 J. J. Carter, L. A. Koutsky, G. C. Wipf, et al., “The Natural History of Human Papillomavirus Type 16 Capsid Antibodies among a Cohort of University Women,” Journal of Infectious Disease, Vol. 174, No. 5, 1996, pp. 927-936. http://dx.doi.org/10.1093/infdis/174.5.927
 P E. Castle, T. Shields, R. Kirnbauer, et al., “Sexual Behavior, Human Papillomavirus Type 16 (HPV 16) Infection, and HPV 16 Seropositivity,” Sexually Transmitted Diseases, Vol. 29, No. 3, 2002, pp. 182-187. http://dx.doi.org/10.1097/00007435-200203000-00009
 D. Opalka, C. E. Lachman, S. A. MacMullen, et al., “Simultaneous Quantitation of Antibodies to Neutralizing Epitopes on Virus-Like Particles for Human Papillomavirus Types 6, 11, 16, and 18 by a Multiplexed Luminex Assay,” Clinical and Diagnostic Laboratory Immunology, Vol. 10, No. 1, 2003, pp. 108-115.
 J. L. Belinson, Y. L. Qiao, R. G. Pretorius, et al., “Shanxi Province Cervical Cancer Screening Study: A Cross-Sectional Comparative Trial of Multiple Techniques to Detect Cervical Neoplasia,” Gynecologic Oncology, Vol. 83, No. 2, 2001, pp. 439-444. http://dx.doi.org/10.1006/gyno.2001.6370
 J. L. Belinson, S. Hu, M. Niyazi, et al., “Prevalence of Type-Specific Human Papillomavirus in Endocervical, Upper and Lower Vaginal, Perineal, and Vaginal Self-Collected Specimens; Implications for Vaginal Self-Collection,” International Journal of Cancer, Vol. 127, No. 5, 2010, pp. 1151-1157. http://dx.doi.org/10.1002/ijc.25144
 M. Follen, S. Crain, C. MacAulay, et al., “Optical Technologies for Cervical Neoplasia; Update of an NCI Program Project Grant,” Clinical Advances in Hematology and Oncology, Vol. 3, No. 1, 2005, pp. 41-53.